The order by the U.S. Court of Appeals for the 5th Circuit is almost certain to be appealed to the Supreme Court.

The U.S. Court of Appeals for the 5th Circuit ruled that several decisions the Food and Drug Administration took to make mifepristone more broadly available to women did not take safety concerns into account.